Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7789 in advanced solid tumors
NCT04931654Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of sabestomig in non-small cell lung cancer (NSCLC), gastric cancer (GC) and gastroesophageal junction cancer (6 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Dose-Limiting Toxicity at 18 months and 1 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
sabestomig
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04931654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931654.